

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CONVENIENT HOSPITALS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **CONVENIENT HOSPITALS LIMITED** ("the Company"), for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 52 and Regulation 54 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 52 and Regulation 54 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI): A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 52 and Regulation 54 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. As stated in Note 8 of the Statement, the standalone financial information relating to the quarter ended 30 June 2025, prepared in accordance with Ind AS 34, included in the Statement have been furnished to us by the Management and have not been subjected to audit or review by us. Our conclusion on the Statement is not modified in respect of this matter.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)

Ajay Jhawar
Partner

Membership No.223888
UDIN: 26223888CSNBZS2840

Place: Hyderabad
Date: 12 August 2026

Convenient Hospitals Limited
CIN - U85110MP1993PLC007654
Regd. Office : Near L.I.G. Square, A.B. Road, Indore, Madhya Pradesh - 452 008, India.
Telephone No: 0731-4774444, Fax No. : 0731-254 9095, Email Id: cs.office@carehospitals.com

Statement of Unaudited Standalone Financial Results for the Quarter ended 30 June 2026

Particulars		Quarter ended			(₹ in million)
		30 June 2026	31 March 2026 (Refer note 7)	30 June 2025 (Refer note 8)	Year ended 31 March 2026
		(Unaudited)			(Audited)
I	Income				
	Revenue from operations	576.26	541.17	537.87	2,174.11
	Other income	57.47	306.19	4.09	459.74
	Total income	633.73	847.36	541.96	2,633.85
II	Expenses				
	(i) Purchases of medical consumables and pharmacy items	112.82	103.57	104.07	412.56
	(ii) Changes in inventories of medical consumables and pharmacy items	(2.64)	4.02	(1.57)	1.98
	(iii) Professional fee to consultant doctors	180.46	165.96	175.73	699.98
	(iv) Employee benefits expense	80.82	80.83	76.44	311.56
	(v) Finance costs	332.31	371.26	-	670.20
	(vi) Depreciation and amortisation expense	16.73	17.05	16.68	68.14
	(vii) Other expenses	112.40	230.92	80.43	456.64
	Total expenses	832.90	973.61	451.78	2,621.06
III	(Loss)/Profit before tax (I-II)	(199.17)	(126.25)	90.18	12.79
IV	Tax expense/(credit):				
	(i) Current tax	-	-	26.75	(8.57)
	(ii) Deferred tax	(6.84)	15.77	(3.31)	66.29
	Total tax expense/ (credit)	(6.84)	15.77	23.44	57.72
V	(Loss)/Profit for the period/year (III-IV)	(192.33)	(142.02)	66.74	(44.93)
VI	Other comprehensive income/(loss):				
	(i) Items that will not be reclassified to Statement of Profit and Loss				
	(a) Remeasurement of post-employment benefit obligations	2.82	0.40	-	2.11
	(b) Fair value gain on investments in equity instrument designated at FVTOCI	-	708.13	-	708.13
	(c) Income tax relating to these items	(0.71)	(101.36)	-	(101.79)
	Other comprehensive income/(loss) for the period/year, net of tax	2.11	607.17	-	608.45
VII	Total comprehensive income/(loss) for the period/year (V+VI)	(190.22)	465.15	66.74	563.52
VIII	Paid up equity share capital (Face value of ₹ 10 each)	94.49	94.49	94.49	94.49
IX	Other equity				1,124.72
X	Earnings/ (Loss) per share (Face value of ₹ 10 each)				Annualised
	Basic (in ₹)	Not annualised (20.36)	Not annualised (15.03)	Not annualised 7.06	(4.76)
	Diluted (in ₹)	(20.36)	(15.03)	7.06	(4.76)

See accompanying notes to the Statement of Unaudited Standalone Financials Results



Convenient Hospitals Limited

Notes to the Statement of Unaudited Standalone Financial Results

- 1 The Statement of Unaudited Standalone Financial Results of Convenient Hospitals Limited ("the Company") for the quarter ended 30 June 2026 ('the Statement') has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 (the "Act") read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.
- 2 The Statement has been reviewed by the Audit Committee and approved by the Board of Directors on 12 August 2026. The results for the quarter ended 30 June 2026 has been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have expressed an unmodified review conclusion.
- 3 The Company is primarily engaged in providing Medical and Healthcare Services in India which constitutes a single operating segment as per Ind AS 108 - 'Operating Segments'.
- 4 During the quarter ended 30 June 2026, Quality Care India Limited ('QCIL'), the Holding Company of the Company obtained the approval from National Company Law Tribunal ('NCLT') for the Scheme of Amalgamation by way of merger between QCIL (Transferor Company) and Aster DM Healthcare Limited ('ADMHL'/ Transferee Company). The Scheme became effective 01 July 2026 and the name of ADMHL was changed to Aster DM Quality Care Limited.
- 5 During the previous year, the Company issued 122,500 9.63% Listed, Rated, Secured, Redeemable Non-Convertible Debentures (NCDs) of face value of ₹ 100,000 each aggregating ₹ 12,250 million on private placement basis. These NCDs were listed on BSE Limited on 03 October 2025.

These Non-convertible Debentures are secured by a corporate guarantee provided by Aster DM Quality Care Limited ("Aster DM"/"Holding Company") and first pari-passu charge by way of pledge created by Aster DM over certain shares and securities held in identified subsidiaries (present and future) and first pari-passu charge by way of pledge created by the Company over investments acquired from NCD proceeds.

- 6 The Board of Directors, at its meeting held on 11 March, 2026, approved the incorporation of a wholly owned subsidiary, QCIL Nagpur Private Limited, as a Special Purpose Vehicle (SPV) under the Maha Metro Project, Nagpur. The subsidiary was incorporated on 13 March 2026, with an authorized and fully paid-up share capital of ₹1 million, comprising 1,00,000 equity shares of ₹10 each.

During the quarter ended 30 June 2026, the Company subscribed to the rights issue of QCIL Nagpur Private Limited by investing in its 3,14,922 equity shares amounting to ₹ 1,299.99 million.

- 7 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the year ended 31 March 2026 and the unaudited published figures in respect of nine months ended 31 December 2025, which was subjected to limited review by the statutory auditors.
- 8 The figures for the quarter ended 30 June 2025 are presented based on the information compiled by the management and have not been subjected to a separate audit or review by the statutory auditors. However, the management has exercised necessary diligence to ensure that the financial results for this period provide a true and fair view of the Company affairs.



For and on behalf of Board of Directors of
Convenient Hospitals Limited


Dr. Payan Kumar
Managing Director
DIN - 07506347

Place: Hyderabad
Date: 12 August 2026



Convenient Hospitals Limited

Notes to Statement of Unaudited Standalone Financial Results

Additional Disclosure as per clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended :

Particulars	Quarter ended			Year ended
	30 June 2026	31 March 2026 (Refer note 7)	30 June 2025 (Refer note 8)	31 March 2026
	(Unaudited)			(Audited)
(a) Debt-equity ratio (times)	11.65	9.83	NA	9.83
(b) Debt service coverage ratio (times)	0.45	0.71	NA	1.12
(c) Interest service coverage ratio (times)	0.40	0.66	NA	1.02
(d) Outstanding redeemable preference shares (quantity and value)	NA	NA	NA	NA
(e) Capital redemption reserve/debenture redemption reserve *	NA	NA	NA	NA
(f) Net worth (₹ in million)	1,028.99	1,219.21	1,389.60	1,219.21
(g) Net profit after tax (₹ in million)	(192.33)	(142.02)	66.74	(44.93)
(h) Earnings per share **				
a) Basic (in ₹)	(20.36)	(15.03)	7.06	(4.76)
b) Diluted (in ₹)	(20.36)	(15.03)	7.06	(4.76)
(i) Current ratio (times)	5.23	5.11	1.67	5.11
(j) Long term debt to working capital (times)	4.68	2.91	NA	2.91
(k) Bad debts to Account receivable ratio (%)	NA	6.85%	NA	6.85%
(l) Current liability ratio (%)	4.73%	7.60%	85.45%	7.60%
(m) Total debts to total assets (%)	86.74%	83.16%	NA	83.16%
(n) Debtors' turnover (in days)	7.24	5.87	5.52	26.21
(o) Inventory turnover (in days)	2.66	2.60	2.34	10.06
(p) Operating margin (%)	26.01%	48.42%	19.87%	34.55%
(q) Net profit margin (%)	-33.38%	-26.24%	12.41%	-2.07%

* Not required in respect of privately placed debentures in terms of Rule 18(7)(b)(iii) of Companies (Share Capital and Debenture) Rules, 2014

** The earnings per equity share are not annualised for the the quarters

NA = Not applicable

Formulae for computation of ratios are as follows :

- (a) Debt-equity ratio = (Non-Current Borrowings + Current Borrowings)/ Network
- (b) Debt service coverage ratio = Earnings before interest, tax, depreciation and amortisation (EBITDA) / (Interest Expense+Principal repayments)
- (c) Interest service coverage ratio = Earnings before interest and tax (EBIT)/Finance Cost
- (d) Net worth = Equity share capital + Retained earnings
- (i) Current ratio = Current Assets/Current liabilities
- (j) Long term debt to working capital = (Non - current borrowings+ Current maturities of long term borrowings)/ (Current Assets- Current liabilities excluding current maturities of long term borrowings)
- (k) Bad debts to Account receivable ratio = Bad debts/Average account receivable
- (l) Current liability ratio = Current liability/ Total Liabilities
- (m) Total debts to total assets = Non-current borrowings/Total Assets
- (n) Debtors' turnover = Revenue from Operations/Average Accounts Receivable
- (o) Inventory turnover = Cost of Goods Sold (COGS) (Purchases of medical consumables and pharmacy items + Changes in inventories of medical consumables and pharmacy items)/ Average Inventory
- (p) Operating margin percent = EBITDA/Revenue from Operations
- (q) Net profit margin percent = Net profit/ Revenue from Operations

